Skip to content
S1654Senate2023-2024 Session

Test Newborns for SMA

Official title

“Relates to the testing of newborns for spinal muscular atrophy and public education thereon”

Sponsor Robert OrttSD-62+1 co-sponsorAffects Health
Status
In Senate Committee
Health
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill requires newborns in New York to be tested for spinal muscular atrophy and mandates public education about the disease.

Why it matters

  1. Early detection of spinal muscular atrophy (SMA) through required newborn screening can lead to faster diagnosis and earlier treatment, which is crucial for improving health outcomes and reducing disability or mortality associated with the disease.

  2. Mandated public education ensures that parents and prospective parents are better informed about SMA, its risks, symptoms, and available treatments, empowering families to make timely medical decisions and seek support resources.

  3. Hospitals will be required to provide up-to-date, standardized information about SMA to families, potentially reducing confusion, misinformation, and disparities in awareness or access to care across different communities.

  4. By formalizing the Department of Health’s role in both testing and education, the bill could help drive broader policy efforts to address rare genetic diseases and integrate newborn screening with ongoing public health initiatives.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Test Newborns for SMA

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Robert Ortt

Senator · Senate District 62

1 Co-sponsor

History

  1. Referred to health
  2. Referred to health

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

1654

2023-2024 Regular Sessions

IN SENATE

January 13, 2023

Introduced by Sen. ORTT -- read twice and ordered printed, and when printed to be committed to the Committee on Health

AN ACT to amend the public health law, in relation to the testing of newborns for spinal muscular atrophy and public education thereon

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subdivision 1 of section 2500-a of the public health law, as amended by chapter 730 of the laws of 2021, paragraph (j) as amended by chapter 70 of the laws of 2022, is amended to read as follows:

1. It shall be the duty of the administrative officer or other person in charge of each institution caring for infants twenty-eight days or less of age and the person required in pursuance of the provisions of section forty-one hundred thirty of this chapter to register the birth of a child, to cause to have administered to every such infant or child in its or his care a test for diseases and conditions designated by the commissioner under regulations of the commissioner, and for:

(a) Phenylketonuria[.];

(b) Homozygous sickle cell disease[.];

(c) Hypothyroidism[.];

(d) Branched-chain ketonuria[.];

(e) Galactosemia[.];

(f) Homocystinuria[.];

(g) Critical congenital heart defects through pulse oximetry screening[.];

(h) With regard to any newborn infant who is identified as, or suspected of, having a hearing impairment as a result of a screening conducted pursuant to section twenty-five hundred-g of this title, a urine polymerase chain reaction (PCR) test for cytomegalovirus, unless the parent of the infant objects thereto; provided that if the commissioner determines that another test for cytomegalovirus is diagnostically equivalent to or better than the urine polymerase chain reaction

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD05581-01-3

test, the commissioner may, by regulation under this section, allow or require the use of that other test[.];

(i) Adrenoleukodystrophy[.];

(j) Glucose-6-phosphate dehydrogenase deficiency using a quantitative enzymatic test or other diagnostic test in cases where: the newborn infant presents with hemolytic anemia, hemolytic jaundice, or early-onset increasing neonatal jaundice, that is, jaundice (bilirubin level greater than fortieth percentile for age in hours) persisting beyond the day of birth through the week after birth; the newborn infant has been admitted to the hospital for jaundice following birth; or the biological parent of the newborn infant indicates a family, racial, or ethnic risk of glucose-6-phosphate dehydrogenase deficiency, including having significant African, Asian, Mediterranean, or Middle Eastern ancestry; and

(k) spinal muscular atrophy.

§ 2. The public health law is amended by adding a new section 2500-m to read as follows:

§ 2500-m. Spinal muscular atrophy public education. 1. The department shall develop and publish informational materials for women who may become pregnant, expectant parents and parents of infants regarding:

(a) the incidence of spinal muscular atrophy;

(b) the risks of spinal muscular atrophy;

(c) birth defects caused by spinal muscular atrophy;

(d) methods of diagnosing spinal muscular atrophy; and

(e) available methods of treating spinal muscular atrophy and resources available for families of children born with spinal muscular atrophy.

2. The department shall publish the information required pursuant to subdivision one of this section on its internet website, and distribute information regarding birth defects, treatment and resources to all hospitals performing spinal muscular atrophy testing pursuant to section twenty-five hundred-a of this title.

3. The department may promulgate rules to implement the purposes of this section.

§ 3. This act shall take effect immediately; except that section one of this act shall take effect on the one hundred twentieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of section one of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law, in relation to the testing of newborns for spinal muscular atrophy and public education thereon

Purpose

This legislation requires that a test be undertaken on newborns for spinal muscular atrophy and that a spinal muscular atrophy public educa- tion program be undertaken.

Summary of specific provisions

Section 1 amends Subdivision (a) of section 2500a of the public health law to add spinal muscular atrophy to the list of tests performed on an infant prior to 28 days.

Section 2 adds a new subdivision 2500-1 by creating a spinal muscular atrophy public education program.

Section 3 is the effective date.

Justification

Spinal Muscular Atrophy is a disease that affects motor nerve cells of the spinal cord, taking away an individual's ability to walk, eat and breathe. It is the NUMBER ONE genetic cause of death for infants. Importantly, In December of 2016 the first ever treatment for SMA was approved, making this disease treatable making early detection even that more important. By requiring screening for newborns this genetic disease can be identified as quickly as possible and death or degradation of quality of life can be prevented.

Prior legislative history

2021-2022: S. 3622 Referred to Health

2019-2020: S3355 Referred to Health

2017-2018: S7048 committed to Finance

Fiscal implications

None.

Effective date

This act shall take effect immediately; except for section one which will take effect in 120 days.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.